Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
May 31, 2018
InDex Pharmaceuticals

InDex Pharmaceuticals will participate in the Digestive Disease Week (DDW)

InDex Pharmaceuticals Holding AB (publ) today announced that the company will present two posters at the Digestive Disease Week (DDW). DDW is the largest congress in the world within gastroenterology. The congress is held in Washington DC, US on June 2-5, 2018.

InDex Pharmaceuticals will participate in the Digestive Disease Week (DDW)

InDex Pharmaceuticals Holding AB (publ) today announced that the company will present two posters at the Digestive Disease Week (DDW). DDW is the largest congress in the world within gastroenterology. The congress is held in Washington DC, US on June 2-5, 2018.

May 31, 2018 – InDex Pharmaceuticals Holding AB (publ) today announced that the company will present two posters at the Digestive Disease Week (DDW). DDW is the largest congress in the world within gastroenterology. The congress is held in Washington DC, US on June 2-5, 2018.

The first poster will be presented during the poster session on Sunday June 3 and has the title A retrospective analysis of the clinical application of the multigene analysis test DiBiCol® to differentiate between ulcerative colitis, Crohn’s disease and non-IBD. The poster presents a retrospective analysis of the diagnostic test DiBiCol®, showing that it can be a useful tool to support physicians in the diagnosis of inflammatory bowel disease (IBD) and to differentiate Crohn’s disease from ulcerative colitis and non-IBD.

The second poster has the title The TLR9 agonist cobitolimod modulates the immune system in ulcerative colitis by balancing the Th17/Treg cell response and will be presented during the poster session on Tuesday June 5. The poster includes mechanism of action data on cobitolimod both from an experimental model of colitis and from ulcerative colitis patients, showing that cobitolimod can modulate the immune system in ulcerative colitis by balancing the mucosal Th17/Treg cell response.

The data were previously presented at the European Crohn’s and Colitis Organisation (ECCO) Congress in Vienna in February 2018.

Abstracts of the posters are available on the DDW homepage (www.ddw.org).

For more information:
Peter Zerhouni, CEO
Phone: +46 8 508 847 35
E-mail: peter.zerhouni@indexpharma.com

InDex Pharmaceuticals in brief

InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm. Redeye AB is the company’s Certified Adviser. For more information, please visit www.indexpharma.com

Documents

Press release - InDex Pharmaceuticals will participate in the Digestive Disease Week (DDW)
31 May 2018
English

Last updated:
May 31, 2018

InDex Pharmaceuticals

InDex Pharmaceuticals lead drug candidate is cobitolimod – a new type of drug that can help patients back to a normal life. InDex has also developed a platform of patent protected substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

Click here to read more about us!
Get in touch with us!
Visit us

InDex Pharmaceuticals Holding AB (publ)
Tomtebodavägen 23a
SE-171 77 Stockholm, Sweden

Send us mail

May 31, 2018 – InDex Pharmaceuticals Holding AB (publ) today announced that the company will present two posters at the Digestive Disease Week (DDW). DDW is the largest congress in the world within gastroenterology. The congress is held in Washington DC, US on June 2-5, 2018.

The first poster will be presented during the poster session on Sunday June 3 and has the title A retrospective analysis of the clinical application of the multigene analysis test DiBiCol® to differentiate between ulcerative colitis, Crohn’s disease and non-IBD. The poster presents a retrospective analysis of the diagnostic test DiBiCol®, showing that it can be a useful tool to support physicians in the diagnosis of inflammatory bowel disease (IBD) and to differentiate Crohn’s disease from ulcerative colitis and non-IBD.

The second poster has the title The TLR9 agonist cobitolimod modulates the immune system in ulcerative colitis by balancing the Th17/Treg cell response and will be presented during the poster session on Tuesday June 5. The poster includes mechanism of action data on cobitolimod both from an experimental model of colitis and from ulcerative colitis patients, showing that cobitolimod can modulate the immune system in ulcerative colitis by balancing the mucosal Th17/Treg cell response.

The data were previously presented at the European Crohn’s and Colitis Organisation (ECCO) Congress in Vienna in February 2018.

Abstracts of the posters are available on the DDW homepage (www.ddw.org).

For more information:
Peter Zerhouni, CEO
Phone: +46 8 508 847 35
E-mail: peter.zerhouni@indexpharma.com

InDex Pharmaceuticals in brief

InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm. Redeye AB is the company’s Certified Adviser. For more information, please visit www.indexpharma.com

Documents

Press release - InDex Pharmaceuticals will participate in the Digestive Disease Week (DDW)
31 May 2018
English

Last updated:
May 31, 2018

InDex Pharmaceuticals

InDex Pharmaceuticals lead drug candidate is cobitolimod – a new type of drug that can help patients back to a normal life. InDex has also developed a platform of patent protected substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

Click here to read more about us!
Get in touch with us!
Visit us

InDex Pharmaceuticals Holding AB (publ)
Tomtebodavägen 23a
SE-171 77 Stockholm, Sweden

Send us mail